Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review
Although COVID-19 vaccination decreases the risk of severe illness, it is unclear whether vaccine administration may impact the prevalence of long-COVID. The aim of this systematic review is to investigate the association between COVID-19 vaccination and long-COVID symptomatology. MEDLINE, CINAHL, P...
Saved in:
| Published in: | EClinicalMedicine Vol. 53; p. 101624 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
Elsevier Ltd
01.11.2022
Elsevier |
| Subjects: | |
| ISSN: | 2589-5370, 2589-5370 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Although COVID-19 vaccination decreases the risk of severe illness, it is unclear whether vaccine administration may impact the prevalence of long-COVID. The aim of this systematic review is to investigate the association between COVID-19 vaccination and long-COVID symptomatology.
MEDLINE, CINAHL, PubMed, EMBASE, and Web of Science databases, as well as medRxiv and bioRxiv preprint servers were searched up to June 20, 2022. Peer-reviewed studies or preprints monitoring multiple symptoms appearing after acute SARS-CoV-2 infection either before or after COVID-19 vaccination collected by personal, telephone or electronic interviews were included. The methodological quality of the studies was assessed using the Newcastle-Ottawa Scale.
From 2584 studies identified, 11 peer-reviewed studies and six preprints were included. The methodological quality of 82% (n=14/17) studies was high. Six studies (n=17,256,654 individuals) investigated the impact of vaccines before acute SARS-CoV-2 infection (vaccine-infection-long-COVID design). Overall, vaccination was associated with reduced risks or odds of long-COVID, with preliminary evidence suggesting that two doses are more effective than one dose. Eleven studies (n=36,736 COVID-19 survivors) investigated changes in long-COVID symptoms after vaccination (infection-long-COVID-vaccine design). Seven articles showed an improvement in long-COVID symptoms at least one dose post-vaccination, while four studies reported no change or worsening in long-COVID symptoms after vaccination.
Low level of evidence (grade III, case-controls, cohort studies) suggests that vaccination before SARS-CoV-2 infection could reduce the risk of subsequent long-COVID. The impact of vaccination in people with existing long-COVID symptoms is still controversial, with some data showing changes in symptoms and others did not. These assumptions are limited to those vaccines used in the studies.
The LONG-COVID-EXP-CM study supported by a grant of Comunidad de Madrid. |
|---|---|
| AbstractList | Although COVID-19 vaccination decreases the risk of severe illness, it is unclear whether vaccine administration may impact the prevalence of long-COVID. The aim of this systematic review is to investigate the association between COVID-19 vaccination and long-COVID symptomatology.BackgroundAlthough COVID-19 vaccination decreases the risk of severe illness, it is unclear whether vaccine administration may impact the prevalence of long-COVID. The aim of this systematic review is to investigate the association between COVID-19 vaccination and long-COVID symptomatology.MEDLINE, CINAHL, PubMed, EMBASE, and Web of Science databases, as well as medRxiv and bioRxiv preprint servers were searched up to June 20, 2022. Peer-reviewed studies or preprints monitoring multiple symptoms appearing after acute SARS-CoV-2 infection either before or after COVID-19 vaccination collected by personal, telephone or electronic interviews were included. The methodological quality of the studies was assessed using the Newcastle-Ottawa Scale.MethodsMEDLINE, CINAHL, PubMed, EMBASE, and Web of Science databases, as well as medRxiv and bioRxiv preprint servers were searched up to June 20, 2022. Peer-reviewed studies or preprints monitoring multiple symptoms appearing after acute SARS-CoV-2 infection either before or after COVID-19 vaccination collected by personal, telephone or electronic interviews were included. The methodological quality of the studies was assessed using the Newcastle-Ottawa Scale.From 2584 studies identified, 11 peer-reviewed studies and six preprints were included. The methodological quality of 82% (n=14/17) studies was high. Six studies (n=17,256,654 individuals) investigated the impact of vaccines before acute SARS-CoV-2 infection (vaccine-infection-long-COVID design). Overall, vaccination was associated with reduced risks or odds of long-COVID, with preliminary evidence suggesting that two doses are more effective than one dose. Eleven studies (n=36,736 COVID-19 survivors) investigated changes in long-COVID symptoms after vaccination (infection-long-COVID-vaccine design). Seven articles showed an improvement in long-COVID symptoms at least one dose post-vaccination, while four studies reported no change or worsening in long-COVID symptoms after vaccination.FindingsFrom 2584 studies identified, 11 peer-reviewed studies and six preprints were included. The methodological quality of 82% (n=14/17) studies was high. Six studies (n=17,256,654 individuals) investigated the impact of vaccines before acute SARS-CoV-2 infection (vaccine-infection-long-COVID design). Overall, vaccination was associated with reduced risks or odds of long-COVID, with preliminary evidence suggesting that two doses are more effective than one dose. Eleven studies (n=36,736 COVID-19 survivors) investigated changes in long-COVID symptoms after vaccination (infection-long-COVID-vaccine design). Seven articles showed an improvement in long-COVID symptoms at least one dose post-vaccination, while four studies reported no change or worsening in long-COVID symptoms after vaccination.Low level of evidence (grade III, case-controls, cohort studies) suggests that vaccination before SARS-CoV-2 infection could reduce the risk of subsequent long-COVID. The impact of vaccination in people with existing long-COVID symptoms is still controversial, with some data showing changes in symptoms and others did not. These assumptions are limited to those vaccines used in the studies.InterpretationLow level of evidence (grade III, case-controls, cohort studies) suggests that vaccination before SARS-CoV-2 infection could reduce the risk of subsequent long-COVID. The impact of vaccination in people with existing long-COVID symptoms is still controversial, with some data showing changes in symptoms and others did not. These assumptions are limited to those vaccines used in the studies.The LONG-COVID-EXP-CM study supported by a grant of Comunidad de Madrid.FundingThe LONG-COVID-EXP-CM study supported by a grant of Comunidad de Madrid. Background: Although COVID-19 vaccination decreases the risk of severe illness, it is unclear whether vaccine administration may impact the prevalence of long-COVID. The aim of this systematic review is to investigate the association between COVID-19 vaccination and long-COVID symptomatology. Methods: MEDLINE, CINAHL, PubMed, EMBASE, and Web of Science databases, as well as medRxiv and bioRxiv preprint servers were searched up to June 20, 2022. Peer-reviewed studies or preprints monitoring multiple symptoms appearing after acute SARS-CoV-2 infection either before or after COVID-19 vaccination collected by personal, telephone or electronic interviews were included. The methodological quality of the studies was assessed using the Newcastle-Ottawa Scale. Findings: From 2584 studies identified, 11 peer-reviewed studies and six preprints were included. The methodological quality of 82% (n=14/17) studies was high. Six studies (n=17,256,654 individuals) investigated the impact of vaccines before acute SARS-CoV-2 infection (vaccine-infection-long-COVID design). Overall, vaccination was associated with reduced risks or odds of long-COVID, with preliminary evidence suggesting that two doses are more effective than one dose. Eleven studies (n=36,736 COVID-19 survivors) investigated changes in long-COVID symptoms after vaccination (infection-long-COVID-vaccine design). Seven articles showed an improvement in long-COVID symptoms at least one dose post-vaccination, while four studies reported no change or worsening in long-COVID symptoms after vaccination. Interpretation: Low level of evidence (grade III, case-controls, cohort studies) suggests that vaccination before SARS-CoV-2 infection could reduce the risk of subsequent long-COVID. The impact of vaccination in people with existing long-COVID symptoms is still controversial, with some data showing changes in symptoms and others did not. These assumptions are limited to those vaccines used in the studies. Funding: The LONG-COVID-EXP-CM study supported by a grant of Comunidad de Madrid. Although COVID-19 vaccination decreases the risk of severe illness, it is unclear whether vaccine administration may impact the prevalence of long-COVID. The aim of this systematic review is to investigate the association between COVID-19 vaccination and long-COVID symptomatology. MEDLINE, CINAHL, PubMed, EMBASE, and Web of Science databases, as well as medRxiv and bioRxiv preprint servers were searched up to June 20, 2022. Peer-reviewed studies or preprints monitoring multiple symptoms appearing after acute SARS-CoV-2 infection either before or after COVID-19 vaccination collected by personal, telephone or electronic interviews were included. The methodological quality of the studies was assessed using the Newcastle-Ottawa Scale. From 2584 studies identified, 11 peer-reviewed studies and six preprints were included. The methodological quality of 82% ( =14/17) studies was high. Six studies ( =17,256,654 individuals) investigated the impact of vaccines before acute SARS-CoV-2 infection (vaccine-infection-long-COVID design). Overall, vaccination was associated with reduced risks or odds of long-COVID, with preliminary evidence suggesting that two doses are more effective than one dose. Eleven studies ( =36,736 COVID-19 survivors) investigated changes in long-COVID symptoms after vaccination (infection-long-COVID-vaccine design). Seven articles showed an improvement in long-COVID symptoms at least one dose post-vaccination, while four studies reported no change or worsening in long-COVID symptoms after vaccination. Low level of evidence (grade III, case-controls, cohort studies) suggests that vaccination before SARS-CoV-2 infection could reduce the risk of subsequent long-COVID. The impact of vaccination in people with existing long-COVID symptoms is still controversial, with some data showing changes in symptoms and others did not. These assumptions are limited to those vaccines used in the studies. The LONG-COVID-EXP-CM study supported by a grant of Comunidad de Madrid. SummaryBackgroundAlthough COVID-19 vaccination decreases the risk of severe illness, it is unclear whether vaccine administration may impact the prevalence of long-COVID. The aim of this systematic review is to investigate the association between COVID-19 vaccination and long-COVID symptomatology. MethodsMEDLINE, CINAHL, PubMed, EMBASE, and Web of Science databases, as well as medRxiv and bioRxiv preprint servers were searched up to June 20, 2022. Peer-reviewed studies or preprints monitoring multiple symptoms appearing after acute SARS-CoV-2 infection either before or after COVID-19 vaccination collected by personal, telephone or electronic interviews were included. The methodological quality of the studies was assessed using the Newcastle-Ottawa Scale. FindingsFrom 2584 studies identified, 11 peer-reviewed studies and six preprints were included. The methodological quality of 82% ( n=14/17) studies was high. Six studies ( n=17,256,654 individuals) investigated the impact of vaccines before acute SARS-CoV-2 infection (vaccine-infection-long-COVID design). Overall, vaccination was associated with reduced risks or odds of long-COVID, with preliminary evidence suggesting that two doses are more effective than one dose. Eleven studies ( n=36,736 COVID-19 survivors) investigated changes in long-COVID symptoms after vaccination (infection-long-COVID-vaccine design). Seven articles showed an improvement in long-COVID symptoms at least one dose post-vaccination, while four studies reported no change or worsening in long-COVID symptoms after vaccination. InterpretationLow level of evidence (grade III, case-controls, cohort studies) suggests that vaccination before SARS-CoV-2 infection could reduce the risk of subsequent long-COVID. The impact of vaccination in people with existing long-COVID symptoms is still controversial, with some data showing changes in symptoms and others did not. These assumptions are limited to those vaccines used in the studies. FundingThe LONG-COVID-EXP-CM study supported by a grant of Comunidad de Madrid. Although COVID-19 vaccination decreases the risk of severe illness, it is unclear whether vaccine administration may impact the prevalence of long-COVID. The aim of this systematic review is to investigate the association between COVID-19 vaccination and long-COVID symptomatology. MEDLINE, CINAHL, PubMed, EMBASE, and Web of Science databases, as well as medRxiv and bioRxiv preprint servers were searched up to June 20, 2022. Peer-reviewed studies or preprints monitoring multiple symptoms appearing after acute SARS-CoV-2 infection either before or after COVID-19 vaccination collected by personal, telephone or electronic interviews were included. The methodological quality of the studies was assessed using the Newcastle-Ottawa Scale. From 2584 studies identified, 11 peer-reviewed studies and six preprints were included. The methodological quality of 82% (n=14/17) studies was high. Six studies (n=17,256,654 individuals) investigated the impact of vaccines before acute SARS-CoV-2 infection (vaccine-infection-long-COVID design). Overall, vaccination was associated with reduced risks or odds of long-COVID, with preliminary evidence suggesting that two doses are more effective than one dose. Eleven studies (n=36,736 COVID-19 survivors) investigated changes in long-COVID symptoms after vaccination (infection-long-COVID-vaccine design). Seven articles showed an improvement in long-COVID symptoms at least one dose post-vaccination, while four studies reported no change or worsening in long-COVID symptoms after vaccination. Low level of evidence (grade III, case-controls, cohort studies) suggests that vaccination before SARS-CoV-2 infection could reduce the risk of subsequent long-COVID. The impact of vaccination in people with existing long-COVID symptoms is still controversial, with some data showing changes in symptoms and others did not. These assumptions are limited to those vaccines used in the studies. The LONG-COVID-EXP-CM study supported by a grant of Comunidad de Madrid. |
| ArticleNumber | 101624 |
| Author | Gellaco, Ma. Margarita Leticia Fernández-de-las-Peñas, César Lippi, Giuseppe Catahay, Jesus Alfonso Pangilinan, Flos Carmeli Casimiro, Michael Velasco, Jacqueline Veronica Ver, Abbygail Therese Guerrero, Jonathan Jaime Pastrana, Adriel Henry, Brandon Michael Notarte, Kin Israel Peligro, Princess Juneire |
| Author_xml | – sequence: 1 givenname: Kin Israel orcidid: 0000-0002-6055-0886 surname: Notarte fullname: Notarte, Kin Israel organization: Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA – sequence: 2 givenname: Jesus Alfonso surname: Catahay fullname: Catahay, Jesus Alfonso organization: Department of Medicine, Saint Peter's University Hospital, New Brunswick, NJ, USA – sequence: 3 givenname: Jacqueline Veronica orcidid: 0000-0001-7028-8175 surname: Velasco fullname: Velasco, Jacqueline Veronica organization: Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines – sequence: 4 givenname: Adriel orcidid: 0000-0002-4077-0179 surname: Pastrana fullname: Pastrana, Adriel organization: Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines – sequence: 5 givenname: Abbygail Therese orcidid: 0000-0002-2542-2897 surname: Ver fullname: Ver, Abbygail Therese organization: Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines – sequence: 6 givenname: Flos Carmeli surname: Pangilinan fullname: Pangilinan, Flos Carmeli organization: Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines – sequence: 7 givenname: Princess Juneire orcidid: 0000-0002-3768-6937 surname: Peligro fullname: Peligro, Princess Juneire organization: Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines – sequence: 8 givenname: Michael surname: Casimiro fullname: Casimiro, Michael organization: Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines – sequence: 9 givenname: Jonathan Jaime orcidid: 0000-0001-9518-8170 surname: Guerrero fullname: Guerrero, Jonathan Jaime organization: Learning Unit 3, College of Medicine, University of the Philippines Manila, Manila, Philippines – sequence: 10 givenname: Ma. Margarita Leticia surname: Gellaco fullname: Gellaco, Ma. Margarita Leticia organization: Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines – sequence: 11 givenname: Giuseppe orcidid: 0000-0001-9523-9054 surname: Lippi fullname: Lippi, Giuseppe organization: Section of Clinical Biochemistry, University of Verona, Verona, Italy – sequence: 12 givenname: Brandon Michael surname: Henry fullname: Henry, Brandon Michael organization: Clinical Laboratory, Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Centre, OH, USA – sequence: 13 givenname: César orcidid: 0000-0003-3772-9690 surname: Fernández-de-las-Peñas fullname: Fernández-de-las-Peñas, César email: cesar.fernandez@urjc.es organization: Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos, Madrid, Spain |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36051247$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVkl1r2zAUhs3oWLuu_2AMX-7GmSRLllXGoGRfgUIv9nErZOk4VWpLmeRkC-zHT47T0RZGGQgkdN7zHKH3fZ4dOe8gy15iNMMIV29WM9Cddf2MIEL2V4Q-yU4Iq0XBSo6O7pyPs7MYVwghgmgtKvQsOy4rxDCh_CT7vejXSg-5b_P51ffF-wKLfKu0tk4N1rs8reEa8mDjzagxsIXOr61b5p13y2LfkytnRiH8snF4UIq7fj34Pp7nF-kcB-gTV-cBthZ-vsietqqLcHbYT7NvHz98nX8uLq8-LeYXl4XmqBwKbVrFTdVqoXSrUFUrxowmipGmNZXgtNE0FYRijVKYC8Jx24pStDU1WDdVeZotJq7xaiXXwfYq7KRXVu4vfFhKFdKzOpBEgGFAMG04p3Vd1dwYXQuGBGo1q1livZtY603Tg9HghqC6e9D7FWev5dJvpaCYs6pMgNcHQPA_NhAH2duooeuUA7-JknAkeEkrNkpf3Z31d8itfUlwPgl08DEGaKW2w964NNp2EiM5ZkOu5BQXOcZFTnFJzfRB8y3_kbbDB0ByLLkYZNQWnAZjA-ghfan9X8CosVp1N7CDuPKb4FIaJJaRSCS_jEEec0wIQiWjo51v_w14fP4f32UE6Q |
| CitedBy_id | crossref_primary_10_1186_s12889_023_15779_5 crossref_primary_10_3390_biomedicines11071863 crossref_primary_10_1093_ageing_afad204 crossref_primary_10_1186_s41687_024_00797_7 crossref_primary_10_1016_j_vaccine_2024_05_007 crossref_primary_10_1186_s12879_024_10226_1 crossref_primary_10_3389_fmed_2023_1011936 crossref_primary_10_1136_bmjmed_2022_000229 crossref_primary_10_1080_15321819_2024_2429538 crossref_primary_10_3390_diagnostics13111850 crossref_primary_10_1038_s43856_025_00829_3 crossref_primary_10_1111_jep_70180 crossref_primary_10_1002_jmv_28862 crossref_primary_10_3389_fcimb_2024_1293782 crossref_primary_10_1186_s12916_023_03236_4 crossref_primary_10_3390_jpm13020371 crossref_primary_10_3390_v16081256 crossref_primary_10_1016_j_heliyon_2024_e26130 crossref_primary_10_1002_1348_9585_12401 crossref_primary_10_1016_j_virusres_2024_199393 crossref_primary_10_3390_vaccines12010074 crossref_primary_10_1016_j_ajt_2024_06_001 crossref_primary_10_3389_fpubh_2023_1338862 crossref_primary_10_3390_children10030597 crossref_primary_10_1542_peds_2023_062570 crossref_primary_10_1126_scitranslmed_ado2106 crossref_primary_10_1186_s42269_023_01071_4 crossref_primary_10_1007_s11427_024_2643_1 crossref_primary_10_1038_s41598_023_42321_9 crossref_primary_10_3389_fmed_2024_1455729 crossref_primary_10_1016_j_annemergmed_2024_07_009 crossref_primary_10_3390_jcm12237313 crossref_primary_10_3389_fmed_2025_1453167 crossref_primary_10_3390_v15051171 crossref_primary_10_1080_23311886_2023_2299136 crossref_primary_10_3390_jcm12103598 crossref_primary_10_1183_16000617_0254_2022 crossref_primary_10_3390_life14111350 crossref_primary_10_1001_jamanetworkopen_2022_42106 crossref_primary_10_1186_s12889_024_18380_6 crossref_primary_10_1155_2024_7344506 crossref_primary_10_1007_s41666_024_00181_6 crossref_primary_10_1038_s41598_023_46053_8 crossref_primary_10_2196_53522 crossref_primary_10_3390_cells12091297 crossref_primary_10_1016_j_immuni_2024_05_010 crossref_primary_10_1038_s41598_023_43058_1 crossref_primary_10_1038_s41598_023_30583_2 crossref_primary_10_3390_ijms25126389 crossref_primary_10_3390_vaccines11020444 crossref_primary_10_3928_19382359_20230119_01 crossref_primary_10_1111_1440_1681_13776 crossref_primary_10_1016_j_bbi_2023_06_010 crossref_primary_10_1016_j_jinf_2024_106406 crossref_primary_10_1136_bmjresp_2023_001667 crossref_primary_10_1007_s10238_023_01064_7 crossref_primary_10_3389_fimmu_2024_1385858 crossref_primary_10_3390_vaccines13040368 crossref_primary_10_1007_s10238_023_01256_1 crossref_primary_10_1038_s41598_023_38691_9 crossref_primary_10_3390_v15071452 crossref_primary_10_1038_s41598_023_33810_y crossref_primary_10_1038_s43856_024_00549_0 crossref_primary_10_1016_j_vacune_2024_02_005 crossref_primary_10_7759_cureus_80597 crossref_primary_10_1016_j_jacadv_2023_100391 crossref_primary_10_1371_journal_pone_0282451 crossref_primary_10_3390_microorganisms11122959 crossref_primary_10_1016_j_ijid_2023_08_019 crossref_primary_10_1080_21641846_2024_2422258 crossref_primary_10_1007_s00415_024_12212_8 crossref_primary_10_1055_a_2270_3813 crossref_primary_10_3390_v15010042 crossref_primary_10_1016_j_ijregi_2023_08_004 crossref_primary_10_1038_s41562_024_01895_8 crossref_primary_10_1016_j_vaccine_2024_01_101 crossref_primary_10_1007_s00406_024_01868_y crossref_primary_10_1001_jamanetworkopen_2024_59672 crossref_primary_10_1002_ccr3_8953 crossref_primary_10_1016_j_tics_2023_08_008 crossref_primary_10_1016_j_ijid_2023_08_009 crossref_primary_10_1051_bioconf_20237505022 crossref_primary_10_3390_life15050821 crossref_primary_10_4178_epih_e2025024 crossref_primary_10_3390_ijerph191912422 crossref_primary_10_1038_s43856_025_00846_2 crossref_primary_10_7554_eLife_85009 crossref_primary_10_1038_s41590_024_01868_z crossref_primary_10_3389_fmed_2025_1501921 crossref_primary_10_37349_emed_2025_1001310 crossref_primary_10_1016_j_vaccine_2024_126497 crossref_primary_10_1017_S0950268824001687 crossref_primary_10_1186_s12982_025_00898_8 crossref_primary_10_3390_brainsci13010023 crossref_primary_10_1542_peds_2023_064446 crossref_primary_10_3390_healthcare11020197 crossref_primary_10_1038_s41598_023_28839_y crossref_primary_10_1038_s41598_024_57841_1 crossref_primary_10_1093_brain_awad008 crossref_primary_10_1007_s00406_024_01911_y crossref_primary_10_3390_biomedicines10123135 crossref_primary_10_3389_fimmu_2023_1226622 crossref_primary_10_1371_journal_pmed_1004274 crossref_primary_10_3390_v14122629 crossref_primary_10_7759_cureus_37767 crossref_primary_10_3390_vaccines10091481 crossref_primary_10_1111_jnu_12967 crossref_primary_10_1007_s42001_023_00232_9 crossref_primary_10_3389_fpubh_2024_1276391 crossref_primary_10_1371_journal_pone_0315815 crossref_primary_10_3928_24748307_20250219_01 crossref_primary_10_3390_vaccines11111682 crossref_primary_10_7189_jogh_14_05022 crossref_primary_10_1177_10815589251346963 crossref_primary_10_1016_j_medcle_2024_09_001 crossref_primary_10_1177_03000605231198413 crossref_primary_10_3389_fmed_2024_1430444 crossref_primary_10_3390_v15051134 crossref_primary_10_1111_eci_14149 crossref_primary_10_1016_S2213_2600_23_00414_9 crossref_primary_10_3390_vaccines10111924 crossref_primary_10_1111_resp_14596 crossref_primary_10_3390_medicina59020261 crossref_primary_10_1038_s41380_024_02414_x crossref_primary_10_1080_14737175_2023_2185138 crossref_primary_10_3390_ijgi13010031 crossref_primary_10_1093_ofid_ofae545 crossref_primary_10_3390_vaccines11111693 crossref_primary_10_3389_fmolb_2023_1157651 crossref_primary_10_3390_biom15091339 crossref_primary_10_1111_imj_16185 crossref_primary_10_1038_s44325_024_00011_z crossref_primary_10_1007_s00406_023_01557_2 crossref_primary_10_1177_10547738251360170 crossref_primary_10_3389_fpubh_2025_1598246 crossref_primary_10_1038_s44324_025_00072_3 crossref_primary_10_1038_s41467_025_56994_5 crossref_primary_10_1371_journal_pone_0278825 crossref_primary_10_4103_ijnpnd_ijnpnd_73_23 crossref_primary_10_1111_jgs_18584 crossref_primary_10_1007_s12508_024_00431_3 crossref_primary_10_1038_s41598_024_70437_z crossref_primary_10_1001_jamainternmed_2023_3036 crossref_primary_10_3390_vaccines12020183 crossref_primary_10_1186_s12913_023_10064_y crossref_primary_10_1016_j_jinf_2024_106318 crossref_primary_10_1016_j_lana_2024_100984 crossref_primary_10_1136_bmjopen_2023_075301 crossref_primary_10_3390_ijerph20010245 crossref_primary_10_1111_jrh_12796 crossref_primary_10_1002_jmv_28459 crossref_primary_10_1038_s41467_023_41879_2 crossref_primary_10_3389_ijph_2024_1606739 crossref_primary_10_1001_jamainternmed_2023_3033 crossref_primary_10_3389_fimmu_2024_1430214 crossref_primary_10_1016_j_ijid_2023_09_006 crossref_primary_10_4103_atm_atm_202_24 crossref_primary_10_3390_ijerph20031827 crossref_primary_10_2217_fvl_2023_0019 crossref_primary_10_1016_j_jiph_2022_12_018 crossref_primary_10_1093_cid_ciae598 crossref_primary_10_1002_mef2_70004 crossref_primary_10_1016_j_cmi_2025_07_026 crossref_primary_10_1016_j_ypmed_2024_108004 crossref_primary_10_1159_000535391 crossref_primary_10_3390_brainsci13040675 crossref_primary_10_3390_vaccines12060610 crossref_primary_10_1016_j_jpsychores_2023_111441 crossref_primary_10_1007_s11136_024_03726_9 crossref_primary_10_3390_vaccines11051011 crossref_primary_10_3390_biom14101320 crossref_primary_10_1017_S0950268823001279 crossref_primary_10_1080_14760584_2024_2346589 crossref_primary_10_1038_s41467_024_45953_1 crossref_primary_10_3389_fped_2023_1127582 crossref_primary_10_1080_21645515_2024_2345505 crossref_primary_10_3389_fimmu_2024_1450853 crossref_primary_10_1080_29944694_2025_2522695 crossref_primary_10_1039_D5CP01740H crossref_primary_10_1080_21645515_2025_2474772 crossref_primary_10_1093_cid_ciac961 crossref_primary_10_1177_21501319241251941 crossref_primary_10_1186_s12879_024_09076_8 crossref_primary_10_1080_1040841X_2023_2190405 crossref_primary_10_3390_children11020221 crossref_primary_10_3390_vaccines12121427 crossref_primary_10_3389_fimmu_2024_1329162 crossref_primary_10_1016_j_puhe_2024_09_023 crossref_primary_10_1186_s41687_023_00616_5 crossref_primary_10_3390_idr15060072 crossref_primary_10_3390_systems12080312 crossref_primary_10_3390_v15020297 crossref_primary_10_1016_j_jmb_2023_167973 crossref_primary_10_3934_dcdsb_2025115 crossref_primary_10_1186_s12879_023_08600_6 crossref_primary_10_3390_v16121864 crossref_primary_10_3390_v15061370 crossref_primary_10_1016_S1473_3099_22_00801_5 crossref_primary_10_3390_pathogens13030267 crossref_primary_10_1210_clinem_dgad284 crossref_primary_10_1177_20552076231200981 crossref_primary_10_3390_jcm12103511 crossref_primary_10_1016_j_ebiom_2023_104599 crossref_primary_10_1016_j_idnow_2023_104688 crossref_primary_10_1093_ofid_ofae462 crossref_primary_10_1016_j_lfs_2024_122861 crossref_primary_10_3390_ijms241612962 crossref_primary_10_1186_s12916_023_03216_8 crossref_primary_10_3390_v15081776 crossref_primary_10_3389_fmed_2023_1197061 crossref_primary_10_1002_jmv_28364 crossref_primary_10_3390_vaccines12080910 crossref_primary_10_3390_diseases12090199 crossref_primary_10_1016_j_annepidem_2023_11_006 crossref_primary_10_3390_vaccines11030691 crossref_primary_10_1002_cti2_70008 crossref_primary_10_1038_s41598_023_50024_4 crossref_primary_10_1001_jamainternmed_2023_0750 crossref_primary_10_5826_mrm_2024_973 crossref_primary_10_3390_v15030675 crossref_primary_10_3389_fmed_2023_1168628 crossref_primary_10_1371_journal_pone_0309810 crossref_primary_10_1007_s40121_024_00965_8 crossref_primary_10_1016_j_vaccine_2023_02_008 crossref_primary_10_1016_j_vaccine_2024_126664 crossref_primary_10_1371_journal_pone_0288391 crossref_primary_10_1016_j_jinf_2024_106358 crossref_primary_10_1016_j_amjmed_2023_01_011 crossref_primary_10_4103_ijnmr_ijnmr_285_23 crossref_primary_10_3389_fendo_2024_1429848 crossref_primary_10_1007_s15016_023_3012_2 crossref_primary_10_1093_occmed_kqad118 crossref_primary_10_1093_joccuh_uiae062 crossref_primary_10_1016_j_ijid_2023_10_022 crossref_primary_10_3389_fpubh_2024_1384327 crossref_primary_10_1016_j_heliyon_2024_e37664 crossref_primary_10_1038_s41598_025_13043_x crossref_primary_10_3390_healthcare11182500 crossref_primary_10_3389_ijph_2025_1607727 crossref_primary_10_1136_bmjmed_2022_000385 crossref_primary_10_1016_j_ijid_2024_107285 crossref_primary_10_3390_biomedicines12040854 crossref_primary_10_1016_j_ypmed_2023_107752 crossref_primary_10_3390_ijerph20054506 crossref_primary_10_3390_vaccines11091502 crossref_primary_10_1097_MD_0000000000037502 crossref_primary_10_3390_v15020485 crossref_primary_10_1371_journal_pone_0326668 crossref_primary_10_1186_s12913_023_09463_y crossref_primary_10_2147_RMHP_S432153 crossref_primary_10_3389_fpubh_2024_1503907 crossref_primary_10_3389_fimmu_2022_1061686 crossref_primary_10_1038_s41598_023_48502_w crossref_primary_10_1097_MOP_0000000000001221 crossref_primary_10_3389_fimmu_2023_1183258 crossref_primary_10_1016_j_jtha_2023_04_039 crossref_primary_10_1016_j_phrs_2022_106479 crossref_primary_10_3390_vaccines11101590 crossref_primary_10_1136_bmj_2022_074425 crossref_primary_10_1016_S2213_2600_23_00238_2 crossref_primary_10_1016_j_healthplace_2023_103051 crossref_primary_10_1007_s00405_024_08518_y crossref_primary_10_7717_peerj_17723 crossref_primary_10_1016_j_phrs_2022_106485 crossref_primary_10_2147_IDR_S409200 crossref_primary_10_1016_j_tem_2023_03_002 crossref_primary_10_1177_01640275251319325 crossref_primary_10_1371_journal_pone_0309116 crossref_primary_10_1016_j_vaccine_2023_06_008 crossref_primary_10_1186_s12879_025_11468_3 crossref_primary_10_1080_07391102_2023_2195003 crossref_primary_10_2147_IJWH_S457740 crossref_primary_10_1038_s41598_025_94765_w crossref_primary_10_1016_j_vaccine_2024_04_070 crossref_primary_10_3389_fpubh_2024_1320059 crossref_primary_10_3389_fimmu_2022_1070379 crossref_primary_10_1136_bmj_2023_075387 crossref_primary_10_3389_fped_2024_1332020 crossref_primary_10_3390_vaccines12010099 crossref_primary_10_1007_s40291_025_00792_8 crossref_primary_10_1186_s12879_024_09108_3 crossref_primary_10_3390_v16050685 crossref_primary_10_1016_j_vaccine_2023_08_080 crossref_primary_10_1093_pnasnexus_pgad223 crossref_primary_10_1016_j_ijregi_2023_11_015 crossref_primary_10_1002_jmv_29928 crossref_primary_10_1093_infdis_jiae556 crossref_primary_10_1016_j_brainresbull_2023_110702 crossref_primary_10_1038_s41423_023_01095_w crossref_primary_10_2196_50682 crossref_primary_10_3389_fpubh_2023_1155951 crossref_primary_10_3389_fmed_2024_1499239 crossref_primary_10_1080_14760584_2024_2402955 crossref_primary_10_3390_healthcare11020218 crossref_primary_10_1136_bmjph_2023_000060 crossref_primary_10_1186_s12913_023_10170_x crossref_primary_10_3390_vaccines12060688 crossref_primary_10_1016_j_archger_2024_105554 crossref_primary_10_3390_vaccines11020236 crossref_primary_10_1038_s41440_022_01145_2 crossref_primary_10_3389_fmed_2023_1176168 crossref_primary_10_1186_s12916_023_03127_8 crossref_primary_10_3390_jcm14165782 |
| Cites_doi | 10.3390/jcm11061541 10.1007/s15010-021-01696-5 10.1016/S1473-3099(21)00703-9 10.1101/2021.03.11.21253225 10.1038/d41586-021-03732-8 10.1007/s11606-022-07443-2 10.1038/d41586-021-01511-z 10.2139/ssrn.3932953 10.1002/jmv.27689 10.3390/vaccines10010046 10.1093/infdis/jiac136 10.3389/fmed.2021.750378 10.1101/2021.10.03.21264490 10.1101/2021.11.17.21263608 10.1136/bmjgh-2021-005427 10.1101/2022.01.05.22268800 10.1016/j.ijid.2021.11.009 10.21203/rs.3.rs-1062160/v1 10.1016/S1473-3099(21)00460-6 10.1038/s41591-022-01840-0 10.1016/j.cmi.2022.03.016 10.1016/j.bbi.2022.04.013 10.3390/vaccines10050652 10.3390/pathogens11020269 10.1016/j.ejim.2021.06.009 10.1016/j.jclinepi.2009.06.006 10.1038/d41586-021-03495-2 10.1093/fampra/cmab076 10.1101/2021.07.23.21261030 10.1016/S2213-2600(22)00020-0 10.1016/j.cmi.2022.01.014 10.1101/2022.02.23.22271388 10.3389/fmicb.2021.698169 10.1007/s11606-022-07465-w 10.1136/bmj-2021-069676 |
| ContentType | Journal Article |
| Copyright | 2022 The Author(s) The Author(s) 2022 The Author(s). 2022 The Author(s) 2022 |
| Copyright_xml | – notice: 2022 The Author(s) – notice: The Author(s) – notice: 2022 The Author(s). – notice: 2022 The Author(s) 2022 |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1016/j.eclinm.2022.101624 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ (Directory of Open Access Journals) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2589-5370 |
| EndPage | 101624 |
| ExternalDocumentID | oai_doaj_org_article_29ed5e214b77488687ddc895090fc585 PMC9417563 36051247 10_1016_j_eclinm_2022_101624 S2589537022003546 1_s2_0_S2589537022003546 |
| Genre | Journal Article |
| GroupedDBID | .1- .FO 0R~ 53G AAEDW AALRI AAMRU AAXUO AAYWO ABMAC ACLIJ ACVFH ADBBV ADCNI ADVLN AEUPX AEXQZ AFPUW AFRHN AFTJW AIGII AITUG AJUYK AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS APXCP BCNDV EBS EJD FDB GROUPED_DOAJ HYE M41 OK1 ROL RPM SSZ Z5R 0SF 6I. AACTN NCXOZ AAFTH AAYXX CITATION NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c703t-cdfa7d6fc9acfa068a55dc2a52bfd6974bc4cfa9a5baa179271ff939f84d1cb63 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 356 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000860524000004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2589-5370 |
| IngestDate | Fri Oct 03 12:53:20 EDT 2025 Thu Aug 21 18:19:46 EDT 2025 Thu Oct 02 09:55:56 EDT 2025 Thu Jan 02 22:30:18 EST 2025 Thu Nov 27 00:44:44 EST 2025 Tue Nov 18 21:46:29 EST 2025 Sat Nov 29 17:05:46 EST 2025 Tue Feb 25 20:04:40 EST 2025 Sat Nov 29 06:57:08 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Long-COVID symptoms SARS-CoV-2 Vaccine Post-COVID syndrome |
| Language | English |
| License | This is an open access article under the CC BY license. 2022 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c703t-cdfa7d6fc9acfa068a55dc2a52bfd6974bc4cfa9a5baa179271ff939f84d1cb63 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-9518-8170 0000-0001-9523-9054 0000-0002-3768-6937 0000-0002-2542-2897 0000-0001-7028-8175 0000-0002-4077-0179 0000-0002-6055-0886 0000-0003-3772-9690 |
| OpenAccessLink | https://doaj.org/article/29ed5e214b77488687ddc895090fc585 |
| PMID | 36051247 |
| PQID | 2709734653 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_29ed5e214b77488687ddc895090fc585 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9417563 proquest_miscellaneous_2709734653 pubmed_primary_36051247 crossref_citationtrail_10_1016_j_eclinm_2022_101624 crossref_primary_10_1016_j_eclinm_2022_101624 elsevier_sciencedirect_doi_10_1016_j_eclinm_2022_101624 elsevier_clinicalkeyesjournals_1_s2_0_S2589537022003546 elsevier_clinicalkey_doi_10_1016_j_eclinm_2022_101624 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-11-01 |
| PublicationDateYYYYMMDD | 2022-11-01 |
| PublicationDate_xml | – month: 11 year: 2022 text: 2022-11-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | EClinicalMedicine |
| PublicationTitleAlternate | EClinicalMedicine |
| PublicationYear | 2022 |
| Publisher | Elsevier Ltd Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
| References | Hayes, Ingram, Sculthorpe (bib0005) 2021; 8 Marshall (bib0042) 2021; 594 Tsuchida, Hirose, Inoue, Kunishima, Otsubo, Matsuda (bib0028) 2022; 94 Zheng, Shao, Chen, Zhang, Wang, Zhang (bib0001) 2022; 114 Fernández-de-las-Peñas, Palacios-Ceña, Gómez-Mayordomo (bib0007) 2021; 92 Harrison S, Walters B, Zalaya S, Cook M, Clark R. The effectiveness of vaccination against long-COVID: a rapid evidence briefing. 2022. Al-Aly, Bowe, Xie (bib0023) 2022 Graham (bib0016) 2021 Baker, Ledford (bib0014) 2021 Taquet, Dercon, Harrison (bib0024) 2022; 103 Ledford (bib0040) 2021; 599 Nehme, Braillard, Salamun (bib0033) 2022; 37 Ayoubkhani D, Bosworth ML, Statistician † Senior, et al. Risk of long-COVID in people infected with SARS-CoV-2 after two doses of a COVID-19 vaccine: community-based, matched cohort study. Published online 2022. Liberati, Altman, Tetzlaff (bib0017) 2009; 62 Wells G, Tugwell P, O'Connell D, et al. The Newcastle- Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses 2015. Wang, Wang, Li (bib0002) 2022; 9 Al-Aly Z, Bowe B, Xie Y. Long-covid after Breakthrough COVID-19: the post-acute sequelae of breakthrough COVID-19. Research Square. Published online November 2021. Maglietta, Diodati, Puntoni (bib0041) 2022; 11 Venkatesan (bib0013) 2022; 10 Strain, Sherwood, Banerjee, van der Togt, Hishmeh, Rossman (bib0030) 2022; 10 Fernández-de-las-Peñas (bib0003) 2022; 50 Michelen, Manoharan, Elkheir (bib0006) 2021; 6 Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long-COVID: a meta-analysis and systematic review. Massey D, Berrent D, Krumholz H. Breakthrough symptomatic COVID-19 infections leading to long-COVID: report from long-COVID Facebook group poll. Arnold D, Milne A, Samms E, Stadon L, Maskell N, Hamilton F. Are vaccines safe in patients with Long-COVID? A prospective observational study. Peghin, de Martino, Palese (bib0029) 2022; 28 Wisnivesky, Govindarajulu, Bagiella (bib0035) 2022; 37 Alkodaymi, Omrani, Fawzy (bib0009) 2022; 28 Kuodi P, Gorelik Y, Zayyad H, et al. Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021. Antonelli, Penfold, Merino (bib0020) 2022; 22 Ayoubkhani, Bermingham, Pouwels (bib0031) 2022; 377 Johns Hopkins University Coronavirus Resource Centre. COVID-19 dashboard. Published 2022. van Kessel, Olde Hartman, Lucassen, van Jaarsveld (bib0012) 2022; 39 Gaber, Ashish, Unsworth, Martindale (bib0026) 2021; 14 Tran VT, Perrodeau E, Saldanha J, et al. Efficacy of COVID-19 vaccination on the symptoms of patients with long-COVID: a target trial emulation using data from the ComPaRe e-cohort in France. Published online 2021. . Scherlinger, Pijnenburg, Chatelus (bib0027) 2021; 10 Soriano, Murthy, Marshall, Relan, Diaz (bib0004) 2022; 22 Han, Zheng, Daines, Sheikh (bib0010) 2022; 11 Published online 2021. Senjam S, Balhara Y, Kumar P, et al. Assessment of post COVID-19 health problems and its determinants in North India: a descriptive crosssection study. Ontario Agency for Health Protection and Promotion (Public Health Ontario). Impact of vaccination on post-acute COVID-19 syndrome (PACS) – what we know so far. 2022. Proal, VanElzakker (bib0043) 2021; 12 Conlon (bib0015) 2022 Simon MA, Luginbuhl RD, Parker R. Reduced incidence of long-COVID symptoms related to administration of covid-19 vaccines both before COVID-19 diagnosis and up to 12 weeks after. Soriano (10.1016/j.eclinm.2022.101624_bib0004) 2022; 22 Proal (10.1016/j.eclinm.2022.101624_bib0043) 2021; 12 Han (10.1016/j.eclinm.2022.101624_bib0010) 2022; 11 Fernández-de-las-Peñas (10.1016/j.eclinm.2022.101624_bib0003) 2022; 50 Venkatesan (10.1016/j.eclinm.2022.101624_bib0013) 2022; 10 10.1016/j.eclinm.2022.101624_bib0022 Gaber (10.1016/j.eclinm.2022.101624_bib0026) 2021; 14 10.1016/j.eclinm.2022.101624_bib0021 Hayes (10.1016/j.eclinm.2022.101624_bib0005) 2021; 8 Ledford (10.1016/j.eclinm.2022.101624_bib0040) 2021; 599 Marshall (10.1016/j.eclinm.2022.101624_bib0042) 2021; 594 van Kessel (10.1016/j.eclinm.2022.101624_bib0012) 2022; 39 Alkodaymi (10.1016/j.eclinm.2022.101624_bib0009) 2022; 28 Antonelli (10.1016/j.eclinm.2022.101624_bib0020) 2022; 22 10.1016/j.eclinm.2022.101624_bib0037 10.1016/j.eclinm.2022.101624_bib0038 10.1016/j.eclinm.2022.101624_bib0036 Michelen (10.1016/j.eclinm.2022.101624_bib0006) 2021; 6 10.1016/j.eclinm.2022.101624_bib0019 Fernández-de-las-Peñas (10.1016/j.eclinm.2022.101624_bib0007) 2021; 92 10.1016/j.eclinm.2022.101624_bib0039 10.1016/j.eclinm.2022.101624_bib0018 Peghin (10.1016/j.eclinm.2022.101624_bib0029) 2022; 28 10.1016/j.eclinm.2022.101624_bib0011 Strain (10.1016/j.eclinm.2022.101624_bib0030) 2022; 10 10.1016/j.eclinm.2022.101624_bib0034 Liberati (10.1016/j.eclinm.2022.101624_bib0017) 2009; 62 10.1016/j.eclinm.2022.101624_bib0032 Scherlinger (10.1016/j.eclinm.2022.101624_bib0027) 2021; 10 Zheng (10.1016/j.eclinm.2022.101624_bib0001) 2022; 114 Nehme (10.1016/j.eclinm.2022.101624_bib0033) 2022; 37 Wisnivesky (10.1016/j.eclinm.2022.101624_bib0035) 2022; 37 Al-Aly (10.1016/j.eclinm.2022.101624_bib0023) 2022 Conlon (10.1016/j.eclinm.2022.101624_bib0015) 2022 Wang (10.1016/j.eclinm.2022.101624_bib0002) 2022; 9 Maglietta (10.1016/j.eclinm.2022.101624_bib0041) 2022; 11 Baker (10.1016/j.eclinm.2022.101624_bib0014) 2021 Taquet (10.1016/j.eclinm.2022.101624_bib0024) 2022; 103 Tsuchida (10.1016/j.eclinm.2022.101624_bib0028) 2022; 94 Ayoubkhani (10.1016/j.eclinm.2022.101624_bib0031) 2022; 377 Graham (10.1016/j.eclinm.2022.101624_bib0016) 2021 10.1016/j.eclinm.2022.101624_bib0025 10.1016/j.eclinm.2022.101624_bib0008 |
| References_xml | – volume: 594 start-page: 168 year: 2021 end-page: 170 ident: bib0042 article-title: The four most urgent questions about long-COVID publication-title: Nature – volume: 94 start-page: 3416 year: 2022 end-page: 3420 ident: bib0028 article-title: Relationship between changes in symptoms and antibody titers after a single vaccination in patients with long-COVID publication-title: J Med Virol – volume: 28 start-page: 657 year: 2022 end-page: 666 ident: bib0009 article-title: Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis publication-title: Clin Microbiol Inf – volume: 599 start-page: 546 year: 2021 end-page: 548 ident: bib0040 article-title: Do vaccines protect against long-COVID? What the data say publication-title: Nature – reference: Kuodi P, Gorelik Y, Zayyad H, et al. Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021. – volume: 92 start-page: 55 year: 2021 end-page: 70 ident: bib0007 article-title: Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis publication-title: Eur J Int Med – volume: 62 start-page: e1 year: 2009 end-page: e34 ident: bib0017 article-title: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration publication-title: J Clin Epid – volume: 377 year: 2022 ident: bib0031 article-title: Trajectory of long COVID symptoms after COVID-19 vaccination: community based cohort study publication-title: BMJ – reference: Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long-COVID: a meta-analysis and systematic review. – volume: 28 start-page: 1140 year: 2022 end-page: 1148 ident: bib0029 article-title: Post–COVID-19 syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients publication-title: Clin Microbiol Inf – reference: Senjam S, Balhara Y, Kumar P, et al. Assessment of post COVID-19 health problems and its determinants in North India: a descriptive crosssection study. – volume: 10 start-page: 46 year: 2021 ident: bib0027 article-title: Effect of SARS-CoV-2 vaccination on symptoms from post-acute sequelae of COVID-19: results from the nationwide VAXILONG study publication-title: Vaccines – volume: 22 start-page: 43 year: 2022 end-page: 55 ident: bib0020 article-title: Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom studyapp: a prospective, community-based, nested, case-control study publication-title: Lancet Infect Dis – volume: 11 start-page: 269 year: 2022 ident: bib0010 article-title: Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms publication-title: Pathogens – reference: Simon MA, Luginbuhl RD, Parker R. Reduced incidence of long-COVID symptoms related to administration of covid-19 vaccines both before COVID-19 diagnosis and up to 12 weeks after. – volume: 37 start-page: 1585 year: 2022 end-page: 1588 ident: bib0033 article-title: Symptoms after COVID-19 vaccination in patients with post-acute sequelae of SARS-CoV-2 publication-title: J Gen Int Med – volume: 14 start-page: a008 year: 2021 ident: bib0026 article-title: Are mRNA COVID 19 vaccines safe in long-COVID patients? A health care workers perspective publication-title: Br J Med Pract – reference: Johns Hopkins University Coronavirus Resource Centre. COVID-19 dashboard. Published 2022. – volume: 11 start-page: 1541 year: 2022 ident: bib0041 article-title: Prognostic factors for post-COVID-19 syndrome: a systematic review and meta-analysis publication-title: J Clin Med – reference: Arnold D, Milne A, Samms E, Stadon L, Maskell N, Hamilton F. Are vaccines safe in patients with Long-COVID? A prospective observational study. – volume: 10 start-page: e30 year: 2022 ident: bib0013 article-title: Do vaccines protect from long-COVID? publication-title: Lancet RespirMed – reference: Massey D, Berrent D, Krumholz H. Breakthrough symptomatic COVID-19 infections leading to long-COVID: report from long-COVID Facebook group poll. – year: 2022 ident: bib0023 article-title: Long-COVID after breakthrough SARS-CoV-2 infection publication-title: Nat Med – volume: 10 start-page: 652 year: 2022 ident: bib0030 article-title: The impact of COVID vaccination on symptoms of long-COVID: an international survey of people with lived experience of long-COVID publication-title: Vaccines – volume: 37 start-page: 1748 year: 2022 end-page: 1753 ident: bib0035 article-title: Association of vaccination with the persistence of post-COVID symptoms publication-title: J Gen Int Med – reference: Al-Aly Z, Bowe B, Xie Y. Long-covid after Breakthrough COVID-19: the post-acute sequelae of breakthrough COVID-19. Research Square. Published online November 2021. – reference: . Published online 2022. – volume: 9 year: 2022 ident: bib0002 article-title: Real-word effectiveness of global COVID-19 vaccines against SARS-CoV-2 variants: a systematic review and meta-analysis publication-title: Front Med – volume: 50 start-page: 285 year: 2022 end-page: 286 ident: bib0003 article-title: Long-COVID: current definition publication-title: Infection – year: 2021 ident: bib0014 article-title: Coronapod: vaccines and long-COVID, how protected are you? publication-title: Nature – reference: Ontario Agency for Health Protection and Promotion (Public Health Ontario). Impact of vaccination on post-acute COVID-19 syndrome (PACS) – what we know so far. 2022. – year: 2021 ident: bib0016 article-title: Daily briefing: what we know about vaccines and long-COVID publication-title: Nature – reference: Ayoubkhani D, Bosworth ML, Statistician † Senior, et al. Risk of long-COVID in people infected with SARS-CoV-2 after two doses of a COVID-19 vaccine: community-based, matched cohort study. – year: 2022 ident: bib0015 article-title: Daily briefing: vaccination could reduce long-COVID risk publication-title: Nature – volume: 12 year: 2021 ident: bib0043 article-title: Long-COVID or post-acute Sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms publication-title: Front Microbiol – volume: 8 year: 2021 ident: bib0005 article-title: More than 100 persistent symptoms of SARS-CoV-2 (Long-COVID): a scoping review publication-title: Front Med – volume: 22 start-page: e102 year: 2022 end-page: e107 ident: bib0004 article-title: A clinical case definition of post-COVID-19 condition by a Delphi consensus publication-title: Lancet Infect Dis – volume: 39 start-page: 159 year: 2022 end-page: 167 ident: bib0012 article-title: Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review publication-title: FamPract – volume: 6 start-page: 5427 year: 2021 ident: bib0006 article-title: Characterizing long-COVID: a living systematic review publication-title: BMJ Global Health – volume: 103 start-page: 154 year: 2022 end-page: 162 ident: bib0024 article-title: Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections publication-title: Brain, Behav, Immun – reference: Wells G, Tugwell P, O'Connell D, et al. The Newcastle- Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analyses 2015. – volume: 114 start-page: 252 year: 2022 end-page: 260 ident: bib0001 article-title: Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis publication-title: Int J Infect Dis – reference: Tran VT, Perrodeau E, Saldanha J, et al. Efficacy of COVID-19 vaccination on the symptoms of patients with long-COVID: a target trial emulation using data from the ComPaRe e-cohort in France. Published online 2021. – reference: . – reference: . Published online 2021. – reference: Harrison S, Walters B, Zalaya S, Cook M, Clark R. The effectiveness of vaccination against long-COVID: a rapid evidence briefing. 2022. – volume: 11 start-page: 1541 year: 2022 ident: 10.1016/j.eclinm.2022.101624_bib0041 article-title: Prognostic factors for post-COVID-19 syndrome: a systematic review and meta-analysis publication-title: J Clin Med doi: 10.3390/jcm11061541 – volume: 50 start-page: 285 year: 2022 ident: 10.1016/j.eclinm.2022.101624_bib0003 article-title: Long-COVID: current definition publication-title: Infection doi: 10.1007/s15010-021-01696-5 – ident: 10.1016/j.eclinm.2022.101624_bib0037 – volume: 22 start-page: e102 year: 2022 ident: 10.1016/j.eclinm.2022.101624_bib0004 article-title: A clinical case definition of post-COVID-19 condition by a Delphi consensus publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(21)00703-9 – ident: 10.1016/j.eclinm.2022.101624_bib0025 doi: 10.1101/2021.03.11.21253225 – year: 2021 ident: 10.1016/j.eclinm.2022.101624_bib0014 article-title: Coronapod: vaccines and long-COVID, how protected are you? publication-title: Nature doi: 10.1038/d41586-021-03732-8 – volume: 37 start-page: 1585 year: 2022 ident: 10.1016/j.eclinm.2022.101624_bib0033 article-title: Symptoms after COVID-19 vaccination in patients with post-acute sequelae of SARS-CoV-2 publication-title: J Gen Int Med doi: 10.1007/s11606-022-07443-2 – volume: 594 start-page: 168 year: 2021 ident: 10.1016/j.eclinm.2022.101624_bib0042 article-title: The four most urgent questions about long-COVID publication-title: Nature doi: 10.1038/d41586-021-01511-z – ident: 10.1016/j.eclinm.2022.101624_bib0034 doi: 10.2139/ssrn.3932953 – volume: 94 start-page: 3416 year: 2022 ident: 10.1016/j.eclinm.2022.101624_bib0028 article-title: Relationship between changes in symptoms and antibody titers after a single vaccination in patients with long-COVID publication-title: J Med Virol doi: 10.1002/jmv.27689 – volume: 10 start-page: 46 year: 2021 ident: 10.1016/j.eclinm.2022.101624_bib0027 article-title: Effect of SARS-CoV-2 vaccination on symptoms from post-acute sequelae of COVID-19: results from the nationwide VAXILONG study publication-title: Vaccines doi: 10.3390/vaccines10010046 – ident: 10.1016/j.eclinm.2022.101624_bib0008 doi: 10.1093/infdis/jiac136 – volume: 8 year: 2021 ident: 10.1016/j.eclinm.2022.101624_bib0005 article-title: More than 100 persistent symptoms of SARS-CoV-2 (Long-COVID): a scoping review publication-title: Front Med doi: 10.3389/fmed.2021.750378 – ident: 10.1016/j.eclinm.2022.101624_bib0018 – ident: 10.1016/j.eclinm.2022.101624_bib0021 doi: 10.1101/2021.10.03.21264490 – ident: 10.1016/j.eclinm.2022.101624_bib0019 doi: 10.1101/2021.11.17.21263608 – volume: 6 start-page: 5427 year: 2021 ident: 10.1016/j.eclinm.2022.101624_bib0006 article-title: Characterizing long-COVID: a living systematic review publication-title: BMJ Global Health doi: 10.1136/bmjgh-2021-005427 – ident: 10.1016/j.eclinm.2022.101624_bib0032 doi: 10.1101/2022.01.05.22268800 – volume: 114 start-page: 252 year: 2022 ident: 10.1016/j.eclinm.2022.101624_bib0001 article-title: Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis publication-title: Int J Infect Dis doi: 10.1016/j.ijid.2021.11.009 – ident: 10.1016/j.eclinm.2022.101624_bib0038 doi: 10.21203/rs.3.rs-1062160/v1 – volume: 22 start-page: 43 year: 2022 ident: 10.1016/j.eclinm.2022.101624_bib0020 article-title: Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom studyapp: a prospective, community-based, nested, case-control study publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(21)00460-6 – ident: 10.1016/j.eclinm.2022.101624_bib0036 – year: 2022 ident: 10.1016/j.eclinm.2022.101624_bib0023 article-title: Long-COVID after breakthrough SARS-CoV-2 infection publication-title: Nat Med doi: 10.1038/s41591-022-01840-0 – volume: 28 start-page: 1140 year: 2022 ident: 10.1016/j.eclinm.2022.101624_bib0029 article-title: Post–COVID-19 syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients publication-title: Clin Microbiol Inf doi: 10.1016/j.cmi.2022.03.016 – volume: 103 start-page: 154 year: 2022 ident: 10.1016/j.eclinm.2022.101624_bib0024 article-title: Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections publication-title: Brain, Behav, Immun doi: 10.1016/j.bbi.2022.04.013 – volume: 10 start-page: 652 year: 2022 ident: 10.1016/j.eclinm.2022.101624_bib0030 article-title: The impact of COVID vaccination on symptoms of long-COVID: an international survey of people with lived experience of long-COVID publication-title: Vaccines doi: 10.3390/vaccines10050652 – volume: 11 start-page: 269 year: 2022 ident: 10.1016/j.eclinm.2022.101624_bib0010 article-title: Long-term sequelae of COVID-19: a systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms publication-title: Pathogens doi: 10.3390/pathogens11020269 – volume: 92 start-page: 55 year: 2021 ident: 10.1016/j.eclinm.2022.101624_bib0007 article-title: Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis publication-title: Eur J Int Med doi: 10.1016/j.ejim.2021.06.009 – volume: 62 start-page: e1 year: 2009 ident: 10.1016/j.eclinm.2022.101624_bib0017 article-title: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration publication-title: J Clin Epid doi: 10.1016/j.jclinepi.2009.06.006 – volume: 599 start-page: 546 year: 2021 ident: 10.1016/j.eclinm.2022.101624_bib0040 article-title: Do vaccines protect against long-COVID? What the data say publication-title: Nature doi: 10.1038/d41586-021-03495-2 – year: 2021 ident: 10.1016/j.eclinm.2022.101624_bib0016 article-title: Daily briefing: what we know about vaccines and long-COVID publication-title: Nature – volume: 39 start-page: 159 year: 2022 ident: 10.1016/j.eclinm.2022.101624_bib0012 article-title: Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review publication-title: FamPract doi: 10.1093/fampra/cmab076 – ident: 10.1016/j.eclinm.2022.101624_bib0039 doi: 10.1101/2021.07.23.21261030 – volume: 9 year: 2022 ident: 10.1016/j.eclinm.2022.101624_bib0002 article-title: Real-word effectiveness of global COVID-19 vaccines against SARS-CoV-2 variants: a systematic review and meta-analysis publication-title: Front Med – volume: 10 start-page: e30 year: 2022 ident: 10.1016/j.eclinm.2022.101624_bib0013 article-title: Do vaccines protect from long-COVID? publication-title: Lancet RespirMed doi: 10.1016/S2213-2600(22)00020-0 – volume: 28 start-page: 657 year: 2022 ident: 10.1016/j.eclinm.2022.101624_bib0009 article-title: Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis publication-title: Clin Microbiol Inf doi: 10.1016/j.cmi.2022.01.014 – ident: 10.1016/j.eclinm.2022.101624_bib0022 doi: 10.1101/2022.02.23.22271388 – volume: 14 start-page: a008 year: 2021 ident: 10.1016/j.eclinm.2022.101624_bib0026 article-title: Are mRNA COVID 19 vaccines safe in long-COVID patients? A health care workers perspective publication-title: Br J Med Pract – volume: 12 year: 2021 ident: 10.1016/j.eclinm.2022.101624_bib0043 article-title: Long-COVID or post-acute Sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms publication-title: Front Microbiol doi: 10.3389/fmicb.2021.698169 – year: 2022 ident: 10.1016/j.eclinm.2022.101624_bib0015 article-title: Daily briefing: vaccination could reduce long-COVID risk publication-title: Nature – volume: 37 start-page: 1748 year: 2022 ident: 10.1016/j.eclinm.2022.101624_bib0035 article-title: Association of vaccination with the persistence of post-COVID symptoms publication-title: J Gen Int Med doi: 10.1007/s11606-022-07465-w – volume: 377 year: 2022 ident: 10.1016/j.eclinm.2022.101624_bib0031 article-title: Trajectory of long COVID symptoms after COVID-19 vaccination: community based cohort study publication-title: BMJ doi: 10.1136/bmj-2021-069676 – ident: 10.1016/j.eclinm.2022.101624_bib0011 |
| SSID | ssj0002048960 |
| Score | 2.642153 |
| Snippet | Although COVID-19 vaccination decreases the risk of severe illness, it is unclear whether vaccine administration may impact the prevalence of long-COVID. The... SummaryBackgroundAlthough COVID-19 vaccination decreases the risk of severe illness, it is unclear whether vaccine administration may impact the prevalence of... Background: Although COVID-19 vaccination decreases the risk of severe illness, it is unclear whether vaccine administration may impact the prevalence of... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 101624 |
| SubjectTerms | Internal Medicine Long-COVID symptoms Post-COVID syndrome SARS-CoV-2 Vaccine |
| Title | Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2589537022003546 https://www.clinicalkey.es/playcontent/1-s2.0-S2589537022003546 https://dx.doi.org/10.1016/j.eclinm.2022.101624 https://www.ncbi.nlm.nih.gov/pubmed/36051247 https://www.proquest.com/docview/2709734653 https://pubmed.ncbi.nlm.nih.gov/PMC9417563 https://doaj.org/article/29ed5e214b77488687ddc895090fc585 |
| Volume | 53 |
| WOSCitedRecordID | wos000860524000004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ (Directory of Open Access Journals) customDbUrl: eissn: 2589-5370 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002048960 issn: 2589-5370 databaseCode: DOA dateStart: 20180101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagQogL4s3yqIzENSLrOLHNrRQqKkFB4qG9WY4fZas2qZq0EhI_nhk72W4K0nJA2lPsWSczY3tGnu8zIS8DxASQsIWMC6kyXtZ5poJ3mVLBKOly70IECn8QBwdysVCf1676wpqwRA-cFPeKKe9Kz-a8hkBFykoK56xUsM_lwUKsi6tvLtRaMnUUj9e4VBEizEp4h7IQ-Yibi8VdHnGHCERnLD5ifLIvRfr-yfb0Z_h5tYpybVvau0NuD_Ek3UnfcZdc8809cvPjcGJ-n_zajzBI2ga6--n7_ttsruiFsdAYTULhByEgxQpz7HOJoaLHbXOYRRlqGocdkTWzv9LU_Tw57duT7jXdoZes0DQhYh6Qb3vvvu6-z4YbFzILM7_PrAtGuCpYZWwweSVNWTrLTMnq4CpIPWrLoUGZsjYGpjIT8wDWVkFyN7d1VTwkW03b-MeEYmLJ8sJUheUc5GUubM2NYJUv8I6sGSlGfWs70JHjrRjHeqw7O9LJShqtpJOVZiRbSZ0mOo4N_d-gKVd9kUw7PgAX04OL6U0uNiPl6Ah6xKvCCgt_tNwwuPibnO-GZaLTc90xnesv6KTooyzy0_JqXXKIhFKE8w9jvhg9VcNCgac_pvHteaeZQGYmpNObkUfJc1dqKSCphUBPwLgTn57obdrSLH9EMnLFIQCtiif_Q9FPyS38lAT1fEa2-rNz_5zcsBf9sjvbJtfFQm7Hef4bw51UJA |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+COVID-19+vaccination+on+the+risk+of+developing+long-COVID+and+on+existing+long-COVID+symptoms%3A+A+systematic+review&rft.jtitle=EClinicalMedicine&rft.au=Notarte%2C+Kin+Israel&rft.au=Catahay%2C+Jesus+Alfonso&rft.au=Velasco%2C+Jacqueline+Veronica&rft.au=Pastrana%2C+Adriel&rft.date=2022-11-01&rft.eissn=2589-5370&rft.volume=53&rft.spage=101624&rft_id=info:doi/10.1016%2Fj.eclinm.2022.101624&rft_id=info%3Apmid%2F36051247&rft.externalDocID=36051247 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F25895370%2FS2589537022X00114%2Fcov150h.gif |